Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-12-25
2007-12-25
Berch, Mark L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S271000, C544S272000, C514S263350, C514S263360
Reexamination Certificate
active
10901574
ABSTRACT:
The present invention is directed to a metabolite of a xanthine Phosphodiesterase type 5 inhibitor having the following structurederivatives, and formulations thereof, and processes for preparing the same.Further disclosed are methods of treating a physiological disorder, symptom or disease in a patient, comprising administering to the patient an effective amount of the above compound, wherein the physiological disorder, symptom or disease is a urogenital, cardiovascular, cerebrovascular or peripheral vascular disorder, angina pectoris, hypertension, restenosis post angioplasty, endarterectomy, stent introduction, cerebral stroke, a respiratory tract disorder such as an allergic condition associated with atopy, pulmonary hypertension, an ischemic heart disorder, impaired glucose tolerance, diabetes and its related complication, insulin resistance syndrome, hyperglycemia, polycystic ovarian syndrome, a glomerular disorder, renal insufficiency, nephritis, a tubular interstitial disorder, an autoimmune disorder, glaucoma, intestinal motility, cachexia or cancer.
REFERENCES:
patent: 5393755 (1995-02-01), Neustadt et al.
patent: 5409934 (1995-04-01), Smith et al.
patent: 5939419 (1999-08-01), Tulshian et al.
patent: 6821978 (2004-11-01), Chackalamannil et al.
patent: WO 92/05175 (1992-04-01), None
patent: WO 93/23401 (1993-11-01), None
patent: WO 02/24698 (2002-03-01), None
patent: WO 03/101991 (2003-12-01), None
patent: WO 03/101992 (2003-12-01), None
Ahn, H.S., et.al., “Potent Tetracyclic Guanine Inhibitors . . . ”, Journal of Medicinal Chem., Am. Chem. Soc. vol. 40, No. 14, pp. 2196-2210 (1997).
Wang, Y., et.al., “Design and Synthesis of Xanthine Analogues . . . ”, Bioorganic and Medicinal Chemistry Letter, vol. 12, No. 21, pp. 3149-3152, (2002).
International Search Report for PCT/US2004/024525; mailed Dec. 21, 2004; 5 pages.
Alton Kevin B.
Boyle Craig D.
Chowdhury Swapan K.
Ghosal Anima
Patrick James E.
Berch Mark L.
Reinhardt Gerard E.
Schering Corporation
LandOfFree
Metabolite of xanthine Phosphodiesterase 5 inhibitor and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Metabolite of xanthine Phosphodiesterase 5 inhibitor and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Metabolite of xanthine Phosphodiesterase 5 inhibitor and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3872674